Blog
RSS FeedPosted by Michael Wonder on 09 Apr 2025
Catalyst Pharmaceuticals announces Health Canada’s acceptance of Agamree new drug submission with priority review
8 April 2025 - Catalyst Pharmaceuticals today reported that its sub-licensee in Canada, Kye Pharmaceuticals has announced that Health Canada has ...
Posted by Michael Wonder on 02 Apr 2025
Rystiggo now approved for adults with generalised myasthenia gravis in Canada
2 April 2025 - The approval is supported by the pivotal Phase 3 MycarinG study in gMG, which demonstrated that treatment ...
Posted by Michael Wonder on 28 Mar 2025
Takeda’s HyQvia receives expanded market authorisation as maintenance therapy for chronic inflammatory demyelinating polyneuropathy
27 March 2025 - HyQvia is the only up to once monthly (every 2, 3 or 4 weeks) immunoglobulin subcutaneous ...
Posted by Michael Wonder on 27 Mar 2025
ViiV Healthcare announces reimbursement for Apretude for HIV-1 pre-exposure prophylaxis under the Non-Insured Health Benefits (NIHB) Program
25 March 2025 - ViiV Healthcare is pleased to announce that Apretude (cabotegravir tablets and extended release injectable suspension) is ...
Posted by Michael Wonder on 25 Mar 2025
Government of Canada signs bilateral agreement with Quebec for Drugs for Rare Diseases
21 March 2025 - In Canada, one in 12 people live with a rare disease, and for most people affected, the ...
Posted by Michael Wonder on 21 Mar 2025
Hikma announces Health Canada approval of Kloxxado (naloxone hydrochloride) nasal spray 8 mg
20 March 2025 - Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose ...
Posted by Michael Wonder on 20 Mar 2025
Health Canada approves Keytruda for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma, in combination with carboplatin and paclitaxel and then continued as monotherapy
19 March 2025 - Approval is based on the Phase 3 KEYNOTE-868/NRG-GY018 trial. ...
Posted by Michael Wonder on 18 Mar 2025
Zorvye cream 0.15% approved by Health Canada for the treatment of mild to moderate atopic dermatitis in adults and children as young as six years of age
17 March 2025 - Once daily, steroid free topical treatment designed to rapidly reduce itch and proactively support long term disease ...
Posted by Michael Wonder on 18 Mar 2025
Pfizer's Ixifi will be available in Canada as of 1 April 2025
17 March 2025 - Ixifi is available in more than 20 countries and was approved by Health Canada in December 2021. ...
Posted by Michael Wonder on 18 Mar 2025
Skyclarys (omaveloxolone) approval by Health Canada ushers in a new era for Friedreich's ataxia treatment in Canada
17 March 2025 - As the only approved treatment to address disease progression, Skyclarys addresses a long standing gap in the ...
Posted by Michael Wonder on 12 Mar 2025
Celltrion's infliximab, the first monoclonal antibody biosimilar, is now Remdantry in Canada
11 March 2025 - CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy and has ...
Posted by Michael Wonder on 12 Mar 2025
ACCRUFeR (ferric maltol) is now available in Canada as a prescription oral treatment for iron deficiency anaemia
11 March 2025 - ACCRUFeR is the only oral iron therapy approved as a prescription drug in Canada. ...
Posted by Michael Wonder on 11 Mar 2025
Health Canada authorises Lazcluze (lazertinib) in combination with Rybrevant (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer
10 March 2025 - Phase 3 MARIPOSA study showed Lazcluze plus Rybrevant significantly improved progression-free survival, reducing the risk of ...
Posted by Michael Wonder on 08 Mar 2025
Acarizax approved in Canada for treatment of young children
7 March 2025 - ALK today announced that Health Canada has approved ALK’s Acarizax tablet for use in children, aged ...
Posted by Michael Wonder on 07 Mar 2025
Ferring receives Health Canada approval for Rebyota (faecal microbiota, live)
6 March 2025 - A novel first in class microbiome restoration therapy for the prevention of recurrence of C. difficile infection. ...